NeurAxis (NASDAQ:NRXS) CFO Timothy Robert Henrichs Buys 7,593 Shares

NeurAxis, Inc. (NASDAQ:NRXS) CFO Timothy Robert Henrichs bought 7,593 shares of the business’s stock in a transaction on Wednesday, April 1st. The stock was purchased at an average price of $1.96 per share, with a total value of $14,882.28. Following the completion of the transaction, the chief financial officer directly owned 7,593 shares of the company’s stock, valued at $14,882.28. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

NeurAxis Stock Performance

Shares of NRXS stock opened at $7.25 on Friday. NeurAxis, Inc. has a 1 year low of $1.33 and a 1 year high of $7.97. The stock has a market cap of $81.11 million, a PE ratio of -3.94 and a beta of 2.49. The business’s fifty day moving average is $5.80 and its 200-day moving average is $4.15.

Institutional Trading of NeurAxis

Hedge funds have recently bought and sold shares of the company. Citadel Advisors LLC boosted its holdings in shares of NeurAxis by 39.6% in the third quarter. Citadel Advisors LLC now owns 35,627 shares of the company’s stock worth $110,000 after buying an additional 10,103 shares during the period. Geode Capital Management LLC raised its holdings in shares of NeurAxis by 48.8% during the fourth quarter. Geode Capital Management LLC now owns 75,653 shares of the company’s stock valued at $343,000 after acquiring an additional 24,817 shares during the period. State Street Corp acquired a new stake in shares of NeurAxis during the fourth quarter valued at approximately $139,000. Money Concepts Capital Corp purchased a new stake in shares of NeurAxis in the 3rd quarter valued at approximately $103,000. Finally, Manatuck Hill Partners LLC purchased a new stake in shares of NeurAxis in the 2nd quarter valued at approximately $122,000. 11.77% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Craig Hallum lifted their target price on NeurAxis from $8.00 to $13.00 and gave the stock a “buy” rating in a report on Friday, March 20th. One analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $13.00.

NeurAxis Company Profile

NeurAxis (NASDAQ: NRXS) is a clinical-stage biotechnology company focused on the discovery and development of therapeutic candidates for diseases of the central nervous system. The company leverages a proprietary approach to deliver small molecules and biologics across the blood–brain barrier, aiming to address conditions ranging from acute neural injury to chronic neurodegenerative disorders.

NeurAxis advances its pipeline through a combination of in-house research, external collaborations with academic medical centers and contract research organizations, and strategic licensing agreements.